Lucid Diagnostics Inc. (NASDAQ:LUCD) Receives $3.94 Average Price Target from Analysts

Shares of Lucid Diagnostics Inc. (NASDAQ:LUCD) have received a consensus rating of “Moderate Buy” from the five analysts that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $3.9375.

Several brokerages recently weighed in on LUCD. Needham & Company LLC reaffirmed a “buy” rating and issued a $3.00 target price on shares of Lucid Diagnostics in a research report on Thursday. Ascendiant Capital Markets upped their price target on Lucid Diagnostics from $8.00 to $8.25 and gave the stock a “buy” rating in a research note on Wednesday, December 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Lucid Diagnostics in a report on Monday, December 29th. Finally, Wall Street Zen raised Lucid Diagnostics from a “sell” rating to a “hold” rating in a research note on Saturday.

Institutional Investors Weigh In On Lucid Diagnostics

Several institutional investors have recently bought and sold shares of the business. Perkins Capital Management Inc. acquired a new stake in shares of Lucid Diagnostics in the third quarter worth $1,138,000. Ghisallo Capital Management LLC purchased a new position in shares of Lucid Diagnostics in the 3rd quarter valued at $2,990,000. Aberdeen Group plc acquired a new position in shares of Lucid Diagnostics during the 3rd quarter valued at $2,525,000. Cubist Systematic Strategies LLC acquired a new position in shares of Lucid Diagnostics during the 1st quarter valued at $39,000. Finally, JPMorgan Chase & Co. boosted its position in Lucid Diagnostics by 71,026.1% during the 2nd quarter. JPMorgan Chase & Co. now owns 32,718 shares of the company’s stock worth $38,000 after purchasing an additional 32,672 shares during the period. 74.01% of the stock is currently owned by hedge funds and other institutional investors.

Lucid Diagnostics Stock Performance

Shares of LUCD stock opened at $1.12 on Tuesday. Lucid Diagnostics has a one year low of $0.95 and a one year high of $1.80. The company has a 50 day moving average price of $1.30 and a 200 day moving average price of $1.18. The firm has a market capitalization of $154.20 million, a price-to-earnings ratio of -1.17 and a beta of 1.18.

Lucid Diagnostics (NASDAQ:LUCD) last announced its quarterly earnings results on Thursday, March 26th. The company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.03). The business had revenue of $1.50 million for the quarter, compared to the consensus estimate of $1.39 million. As a group, equities analysts forecast that Lucid Diagnostics will post -0.84 EPS for the current fiscal year.

More Lucid Diagnostics News

Here are the key news stories impacting Lucid Diagnostics this week:

• Positive Sentiment: Won expanded access with the U.S. Department of Veterans Affairs and is pushing for Medicare/commercial payer wins, which could materially enlarge addressable market and reimbursement prospects. Lucid Diagnostics signals expanded VA market access and 29% sequential test volume
• Positive Sentiment: Strong test-volume growth: management reported ~29% sequential growth in EsoGuard tests processed (3,664 tests in Q4), indicating improving commercial traction. Q4 2025 Earnings Call Highlights
• Positive Sentiment: Revenue slightly beat consensus ($1.50M reported vs. $1.39M expected), showing top-line improvement versus prior-year quarter. Zacks: Reports Q4 Loss, Beats Revenue Estimates
• Positive Sentiment: Company highlighted strengthened clinical evidence with positive real‑world data (largest reported experience for esophageal precancer detection), which can support adoption and payer discussions. PR Newswire: Business Update & Financial Results
• Positive Sentiment: Analyst backing: Needham reaffirmed a “buy” rating with a $3.00 price target, representing sizable upside from current levels if execution continues. Benzinga: Needham Reaffirms Buy
• Neutral Sentiment: Company hosted a Q4 business update and provided slides/webcast; multiple earnings-call transcripts and slides are available for investors evaluating management commentary and forward guidance. Quarterly Press Release / Slide Deck
• Negative Sentiment: Earnings miss on profitability: Lucid reported a Q4 EPS of -$0.10 vs. consensus -$0.07, a larger-than-expected loss that likely drove near-term selling pressure despite revenue strength. InsiderMonkey: Q4 2025 Earnings Call Transcript

About Lucid Diagnostics

Lucid Diagnostics is a molecular diagnostics company focused on improving early detection of oral and oropharyngeal cancers. The company’s flagship offering, the LucidDx Oral Cytology Brush Test, combines a minimally invasive brush biopsy tool with proprietary laboratory analysis to identify cellular abnormalities indicative of malignancy. Samples collected in dental and medical offices are sent to Lucid’s CLIA-certified and CAP-accredited laboratory, where advanced imaging and cytopathology workflows generate diagnostic reports for clinicians and patients.

Since commencing commercial operations, Lucid Diagnostics has worked to integrate its testing platform into dental practices, oral surgery clinics and ENT specialists across the United States.